D. H. E. 45 Articles

MAP shares surge 192% as migraine drug Levadex meets late-stage study endpoints

28 May 2009

Valeant's 2nd-qtr 2007 income stays constant

13 August 2007

MAP Pharma closes $50M financing

2 April 2007

MAP's Tempo migraine drug sees strong Ph II data

12 March 2007

FDA rejects Pozen's lead migraine product

27 October 2003

Britannia and Novartis collaborate on DHE migraine treatment

29 September 2003

Pozen gets OK for rapid migraine drug dev't

12 August 2002

Xcel leverages neurology presence with double purchase

15 July 2002

BPD/Inhale and Sheffield to work on migraine drug

6 May 2002

Schwarz Leads French Migraine Market

18 August 1998

News In Brief

11 December 1997

First Approvals For Zeneca, Glaxo Wellcome Migraine Products

17 March 1997

Novartis Pipeline: A Good Fit But Cuts Are Expected

18 March 1996

Novartis Pipeline: A Good Fit But Cuts Are Expected

18 March 1996

Sumatriptan Finally Launched In France

3 October 1994

FRANCE BARS IMIGRAN REIMBURSEMENT?

27 June 1994

NEUROPHARMACEUTICAL MARKET IN USA

19 April 1993

DATA FROM SANDOZ' DHE-45 TRIAL

6 July 1992

Showing 1-18 of 18 articles

Go to beginningPrevious
  • 1
NextGo to end